3 December 2020

Sofinnova Partners and Polaris Partners have co-led an oversubscribed CHF 54.0m series A round for Noema Pharma, a Swiss clinical-stage company targeting orphan neurological disorders that licensed in four clinical-stage product-candidates from Roche. Lead product NOE-101 is Phase 2b-ready for two indications: persistent seizures in Tuberous Sclerosis Complex (TSC) and severe pain in Trigeminal Neuralgia (TN) while NOE-105 is in preparation for Phase 2b testing to treat Tourette Syndrome. VISCHER is advising Noema Pharma for both, the financing and the inlicensing transaction. The team is led by Matthias Staehelin (Corporate) with Christian Wyss (Corporate), Nadia Tarolli (Tax), Vincent Reardon (Corporate) and Pauline Pfirter (Corporate).

Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital

You are currently offline. Some pages or content may fail to load.